Finance

Lists
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$353.53
0.00%
(0.00) 1D
Nov 12, 1:07:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Mkt. cap
128.63B
Avg. vol.
14.00
Volume
0.00
52-wk high
R$356.79
52-wk low
R$238.31
Shares outstanding
2.04B
No. of employees
32K
Mkt. cap
128.63B
Avg. vol.
14.00
Volume
0.00
52-wk high
R$356.79
52-wk low
R$238.31
Shares outstanding
2.04B
No. of employees
32K
News stories
From web sources and news partners
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitebms.com
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$1.35 / $1.17
+15.23%beat
Revenue / Est. (USD)
13.07B / 12.72B
+2.72%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
12.50B
11.49B
12.97B
13.07B
Cost of goods sold
3.51B
3.41B
3.71B
4.13B
Cost of revenue
3.51B
3.41B
3.71B
4.13B
Research and development expenses
2.56B
2.24B
2.54B
2.36B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.09B
1.61B
1.82B
1.70B
Operating expense
5.47B
4.28B
4.80B
4.52B
Total operating expenses
8.98B
7.69B
8.51B
8.65B
Operating income
3.52B
3.80B
4.46B
4.42B
Other non operating income
544.00M
125.00M
106.00M
199.00M
EBT including unusual items
1.47B
3.24B
4.09B
2.54B
EBT excluding unusual items
3.81B
3.65B
4.35B
4.33B
Income tax expense
384.00M
561.00M
770.00M
374.00M
Effective tax rate
26.12%
17.32%
18.84%
14.75%
Other operating expenses
-
-
-
-
Net income
1.09B
2.68B
3.32B
2.16B
Net profit margin
8.69%
23.30%
25.57%
16.54%
Earnings per share
1.26
1.58
2.04
1.35
Interest and investment income
148.00M
104.00M
101.00M
118.00M
Interest expense
-432.00M
-406.00M
-403.00M
-400.00M
Net interest expenses
-284.00M
-302.00M
-302.00M
-282.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.54B
4.41B
5.08B
4.76B
Gain or loss from assets sale
-
-34.00M
-142.00M
-10.00M
Upcoming events
AI content may include mistakes. Learn more
Google apps